D-0079-2022 Class III Terminated
FDA drug recall D-0079-2022 was initiated by MACLEODS PHARMA USA, INC on Oct 18, 2021 and is designated Class III. Reason for recall: Out-of-specification test results obtained in Organic Impurities test during analysis of controlled samples. The recall status is terminated (terminated Apr 24, 2024). Affected quantity: 13,260 Blister Packs/238,680 tablets.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 3, 2021
- Initiation Date
- Oct 18, 2021
- Termination Date
- Apr 24, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 13,260 Blister Packs/238,680 tablets
Product description
Rizatriptan Benzoate Orally Disintegrating Tablets 5mg, 12 Tablets (2 x 6 Unit-Dose Tablets) Blister Packs, Rx only, Manufactured for: Macleods Pharma USA Inc. Plainsboro, NJ 08536, Manufactured by: Macleods Pharmaceuticals Ltd. Baddi, Himachal Pradesh, INDIA, NDC 33342-093-41
Reason for recall
Out-of-specification test results obtained in Organic Impurities test during analysis of controlled samples.
Distribution pattern
Nationwide within the United States
Code information
Lot #: BRL2102A, BRL2103A, exp. date 04/2025
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0079-2022
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026